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Abstract
Introduction: Non-functioning pituitary adenomas (NFPA) are often diagnosed late as invasive macroadenomas. The surgical resection 
is usually incomplete and about 50% of patients require additional surgery. Recent data suggest that somatostatin analogues (SSA), so 
important in the pharmacotherapy of acromegaly, can also be effective in the management of NFPA.
Material and methods: We analysed data of patients who had been treated up to 10 years previously with SSA: 40 with acromegaly 
(23 — primary, 17 — recurrent tumours) and 22 with NFPA (4 — primary, 18 — recurrent tumours). Hormonal profile, dynamics of tumour 
size change, ophthalmic syndromes, somatostatin receptor (SSTR) scintigraphy, and immunohistochemistry of SSTR subtypes of operated 
tumours as well as side effects were investigated.
Results: Biochemical cure of acromegaly was achieved in 57.5% of patients, while reduction of tumour size was observed in 37% of 
patients and it was more frequent in not-operated cases. Regarding NFPA, stabilisation of tumour size was noticed in 68% of patients. 
Tumour shrinkage was reported in 9% of cases, but in 23% of the study group the adenoma size increased with indication for reoperation.
Conclusions: The efficacy of SSA in NFPA is much lower in comparison to their well-established effects in the treatment of acromegaly. 
Stabilisation of tumour size, which is observed in the majority of NFPA, is significantly more frequent in comparison to the natural his-
tory of untreated NFPA and our previous studies as well. Analysis of SSTR subtypes is an argument in favour of introduction of novel 
broad-spectrum SSA that may be more effective in the treatment of NFPA. Referring to acromegaly, adenoma size decrease was reported 
more frequently in primary therapy. Considering recurrent tumours better outcomes were achieved in patients who were pre-treated 
with SSA before planned surgery. (Endokrynol Pol 2016; 67 (3): 292–298)
Key words: somatostatin analogue therapy; non-functioning pituitary adenomas; acromegaly; somatostatin receptor scintigraphy; 
immunohistochemistry of somatostatin receptor subtypes
Streszczenie
Wstęp: Nieczynne hormonalnie gruczolaki przysadki (NFPA) są często diagnozowane późno w stadium inwazyjnych makrogruczolaków. 
Mają charakter guzów nawrotowych po niedoszczętnych zabiegach operacyjnych i w około 50% przypadków wymagają reoperacji. 
W ostatnim czasie pojawiają się doniesienia sugerujące, że analogi somatostatyny (SSA), będące podstawą farmakoterapii akromegalii, 
są również skuteczne w leczeniu NFPA.
Materiał i metody: Analizowano wpływ SSA stosowanych do 10 lat u 40 chorych z akromegalią (23 — guzy pierwotne, 17 — nawroto-
we) i 22 chorych z NFPA (4 — guzy pierwotne, 18 — nawrotowe). Badano profil hormonalny, dynamikę zmian wielkości guza, objawy 
okulistyczne ze zmianami w polu widzenia, scyntygrafię receptorów somatostatynowych (SSTR), podtypy SSTR w badaniu immunohi-
stochemicznym operowanych guzów oraz występowanie objawów niepożądanych.
Wyniki: Biochemiczne kryteria wyleczenia akromegalii uzyskano u 57,5% pacjentów, a redukcję wielkości guza obserwowano u 37,5% 
chorych i była ona częstsza u pacjentów nieoperowanych. U chorych z NFPA stabilizację wielkości guza i zaburzeń pola widzenia od-
notowano u 68% pacjentów, u 9% obserwowano zmniejszenie wielkości gruczolaka, a u 23% doszło do wzrostu guza ze wskazaniem do 
kolejnej operacji.
Wnioski: Analogi somatostatyny są mniej skuteczne w leczeniu chorych z NFPA w porównaniu z dobrze znanymi efektami leczenia 
w akromegalii. Stabilizacja wielkości guza dotycząca większości przypadków NFPA leczonych SSA jest obserwowana znacząco częściej 
w porównaniu z naturalnym przebiegiem nieleczonych farmakologicznie NFPA, jak również w porównaniu z wynikami naszych 
poprzednich badań. Analiza podtypów SSTR w NFPA przemawia za wprowadzeniem nowych SSA o szerokim spektrum działania re-
ceptorowego, które mogłyby być bardziej skuteczne w leczeniu NFPA. W odniesieniu do akromegalii zmniejszenie wielkości gruczolaka 
w trakcie farmakoterapii jest częściej obserwowane w terapii pierwotnej. W guzach nawrotowych lepsze wyniki uzyskano w przypadkach 
stosowania SSA przed operacją. (Endokrynol Pol 2016; 67 (3): 292–298)
Słowa kluczowe: leczenie analogami somatostatyny; nieczynne hormonalnie gruczolaki przysadki; akromegalia; scyntygrafia receptorów 
somatostatynowych; immunohistochemia podtypów receptorów somatostatynowych
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Introduction
Treatment of non-functioning pituitary adenomas 
(NFPA) remains a great challenge for endocrinolo-
gists. Diagnosed late, usually in a stadium of macroad-
enomas, frequently with an invasion of the adjacent 
structures, especially cavernous sinus, they regard 
a complex and multidisciplinary approach. Transsphe-
noidal surgery, which remains the first-line treatment, is 
rarely curative. Moreover, tumour residue can regrow 
in up to 65% of cases during long-term follow-up [1, 2]. 
Recommendations for postoperative management of 
NFPA are a debated issue. Some authors suggest “wait 
and see” attitude, while others indicate a priority of 
subsequent operation and/or radiotherapy [3, 4]. As far 
as secondary therapy (i.e. therapy applied after the sur-
gical intervention) is concerned, the use of somatostatin 
analogues (SSA) is proposed, considering the presence 
of somatostatin receptors (SSTR) in NFPA [5, 6]. Recep-
tor scintigraphy and possibly immunohistochemistry 
should be performed for the purpose of SSTR detection 
[7]. The efficacy of SSA in the treatment of NFPA was 
evaluated in a few clinical studies [8, 9]. Stabilisation 
of adenoma size was observed in the overwhelming 
majority of patients; however, single cases of tumour 
shrinkage were also noted [10, 11]. It is difficult to draw 
definite conclusions because of limited clinical data and 
short duration of therapy.
Conversely to NFPA, SSA are considered a main-
stay of the pharmacotherapy of acromegaly. The pre-
dominant expression of SSTR2 and SSTR5, through 
which octreotide and lanreotide act, forms the basis 
for SSA clinical use in GH-secreting pituitary adeno-
mas [12]. The aim of the therapy is to provide clinical 
and biochemical control of the disease and tumour 
shrinkage. Criteria for disease control are defined as an 
age-normalised serum IGF-1 value and a random GH 
level < 1.0 ng/mL in oral glucose tolerance test [13]. Full 
response to somatostatin analogues is also understood 
as a ≥ 20% decrease in tumour volume in primary as 
well as in secondary therapy or at least stabilisation of 
tumour remnant in the case of second-line treatment 
[14]. Some authors suggest the importance of somato-
tropinomas pretreatment with somatostatin analogues 
prior to planned neurosurgery, which can be beneficial, 
especially in the aspect of tumour debulking [15].
Material and methods
A total of 22 patients (13 women, 9 men) at the mean 
age of 52.8 ± 14.0 years with diagnosis of NFPA were 
entered into the database. All tumours represented 
macroadenomas. The smallest one was sized 13 × 14 
× 16 mm. Few giant adenomas were noted with the 
largest one sized 47 × 47 × 42 mm. Cavernous sinus 
invasion was present in 18 cases. Visual field defects 
were noted in 12 patients. Eighteen patients (81.8%) 
were operated, nine of them more than once. Further 
more, 85% of NFPA were found to be gonadotropino-
mas in immunohistochemical staining. Four patients 
with NFPA underwent radiotherapy. Four patients 
were not operated (disqualified or did not agree). 
Referring to positive results of SSTR scintigraphy and 
immunohistochemistry of SSTR subtypes, the decision 
to treat patients with SSA was made. They received 
octreotide LAR 20 mg up to 30 mg or lanreotide 120 
mg every four weeks and the duration of therapy was 
6 months up to 10 years. Moreover, three patients un-
derwent pre-operative treatment with octreotide for 
at least 6-12 months. Twelve patients were additionally 
treated with dopamine agonists because of coexisting 
hyperprolactinaemia. 
Concerning acromegaly, 40 patients (28 women, 
12 men) at the mean age of 51.9 ± 11.5 years were treated 
with the same doses of SSA for 2–10 years. Magnetic 
resonance imaging showed 13 microadenomas and 
27 macroadenomas. Seventeen patients (42.5%), in whom 
only one was with microadenoma, were operated. Two 
patients underwent neurosurgical procedure twice and 
one patient received radiotherapy in the postoperative 
period. In a group of nine patients with macroadeno-
mas SSA was administrated for 6 to 12 months before 
planned surgery in accordance with the current rec-
ommendations of the Polish Society of Endocrinology 
[16]. SSA was used as a primary therapy in 23 patients 
(57.5%). Furthermore, eleven patients received dopa-
mine agonists (bromocriptine or cabergoline) due to 
coexisting hyperprolactinaemia. 
The objective of this clinical study is to evaluate 
the effects of SSA therapy in patients with NFPA in 
comparison to their well-known effects in acromegaly. 
The analysis comprises the results of SSA treatment 
used as primary therapy as well as secondary therapy 
following surgery. Patient’s condition, hormone profile, 
tumour size, visual field, and undesirable effects were 
taken into account.
Results
NFPA
Somatostatin receptor scintigraphy was performed in 
order to qualify patients to the therapy with SSA. Scin-
tigraphy with 99mTc-HYNIC-TOC or 99mTc Tektrotyd (740 
[MBq]) used to be the first choice investigation for the 
visualisation of SSTR2 and SSTR5. Only patients with in-
creased tracer uptake were included in the study (Fig. 1). 
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Additionally, immunohistochemistry of somato-
statin receptor subtypes was performed in part of the 
surgically removed tumour tissue. Strong or moderate 
SSTR2 and/or SSTR 5 immunostaining confirmed the 
decision of SSA therapy (Table I). Interestingly, a strong 
expression of SSTR1 was present in the majority of 
NFPA (66%).
SSA therapy alleviated some symptoms of the dis-
ease. The reported headaches were less intense and in 
one case (patient H.G., 66-year-old woman with giant 
pituitary tumour) even disappeared after three months 
of SSA therapy. Interestingly, the improvement in head-
aches was not correlated with a decrease in tumour size. 
Moreover, no changes in the visual field were observed. 
Figure 1. Somatostatin receptor scintigraphy of representative patient with non-functioning pituitary adenoma — confirmation of 
strong expression of SSTR in the tumour
Rycina 1. Przykład scyntygrafii receptorów somatostatynowych pacjenta z nieczynnym hormonalnie gruczolakiem przysadki — silna 
ekspresja SSTR w guzie
Table I. Immunohistochemistry of somatostatin receptors in non-functioning pituitary adenomas. Interestingly, the strong 
expression of SSTR1 is present in the majority of NFPA (66%)
Tabela I. Immunohistochemia receptorów somatostatynowych w nieczynnych hormonalnie gruczolakach przysadki. Zwraca 
uwagę silny odczyn immunohistochemiczny SSTR1 w większości NFPA (66%)
The patient’s initials SSTR1 SSTR2a SSTR2b SSTR3 SSTR4 SSTR5
W.B. Strong Moderate Moderate Strong Negative Weak
G.I. Weak Moderate Doubtful Weak Negative Strong
K.J. Strong Strong Strong Strong Doubtful Strong
M.J. Strong Strong Moderate Moderate Negative Moderate
R.K. Strong Moderate Moderate Strong Negative Weak
T.M. Moderate Moderate Moderate Moderate Negative Moderate
M.P. Strong Strong Moderate Moderate Negative Weak
S.S. Doubtful Moderate Doubtful Non diagnostic Negative Moderate
L.J. Strong Negative Strong Weak Negative Strong
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Tumour size remained stable in 15 cases. A representa-
tive MRI showing stabilisation of adenoma size in one 
patient with a giant tumour is presented in Figure 2. 
Reduction in tumour size was observed in two 
patients. These patients were pretreated with SSA 
before surgery. After incomplete tumour resection the 
combined treatment with somatostatin analogues and 
dopamine agonists was initiated. An increase in tumour 
size in five patients with NFPA was observed (Table II), 
but there was no deterioration in the visual field. Patient 
B.M. (Table II) was qualified for reoperation; however, 
she did not agree to it. Therefore, treatment with lan-
reotide was initiated. Patient J.K. was advised to start 
therapy with lanreotide because he was disqualified 
Table II. Characteristics of patients with non-functioning pituitary adenomas resistant for somatostatin analogue therapy
Tabela II. Charakterystyka pacjentów z nieczynnymi hormonalnie gruczolakami przysadki opornymi na terapię analogiem 
somatostatyny
Patient’s initials Age Sex Surgery Pharmacotherapy Change in tumour size Time of the therapy
B.M. 56 F Once Octreotide + 
bromocriptine
39 × 32 × 23 mm Æ volume 
increase in 2 mm
16 months
J.K. 60 M 3 times +  
radiotherapy
Octreotide 31 × 32 × 39 mm  
Æ 35 × 30 × 39 mm
18 months
K.J. 49 F 3 times Octreotide 15 × 8 × 8 mm  
Æ 18 × 10 × 12 mm
19 months
K.S. 77 M Not operated Octreotide 13 × 14 × 16 mm  
Æ 18 × 13 × 16 mm
7 months
M.J. 69 F Once Octreotide + 
bromocriptine
26 × 14 × 12 mm 
Æ 26 × 20 × 15 mm 
7 months
Figure 2. Giant NFPA (47 × 47 × 42 mm, patient H.G., 66-year-old woman) with high expression of SSTR2, SSTR3, and SSTR5 in 
receptor scintigraphy (A. 22.11.2013). Stabilisation of tumour size in MRI scans during one-year therapy with somatostatin analogues 
(B. MRI, 4.10.2013, C. MRI, 2.09.2014). Clinically — significant improvement in patient’s headaches three months after introduction 
of the therapy
Rycina 2. Gruczolak olbrzymi NFPA (47 × 47 × 42 mm, pacjentka H.G., 66-letnia kobieta) z silną ekspresją SSTR2, SSTR3 i SSTR5 
w scyntygrafii receptorowej (A. 22.11.2013). Stabilizacja wielkości guza w obrazach MR podczas jednorocznej terapii analogami 
somatostatyny (B. MR, 4.10.2013, C. MR, 2.09.2014). Klinicznie — znaczna poprawa w zakresie bólów głowy u pacjentki trzy miesiące 
po wdrożeniu leczenia
A B C
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from neurosurgery. Patients K.S. and M.J. were treated 
with lanreotide and the therapy resulted in stabilisa-
tion (patient K.S.) and slight reduction of tumour size 
(patient M.J.). Considering patient K.J. we preferred to 
adopt a “wait-and-see” attitude because the therapy 
had been stopped for several months due to lack of 
patient adherence. 
SSA were well-tolerated; however, two patients 
developed asymptomatic cholelithiasis after 20 and 36 
months of treatment, respectively.
Acromegaly
More than half of the acromegalic patients noticed that 
some symptoms improved (headaches, facial features, 
sleep apnoea) while others were relieved (oedema, 
sweating).
Biochemical cure of acromegaly was achieved in 
23 patients (57.5%); 11 of whom were operated. What 
is important, biochemical criteria were fulfilled in eight 
patients who received SSA preoperatively. Biochemi-
cal control of the disease was noted in 12 patients who 
were not operated, and they were treated with SSA as 
primary therapy (52.2% of all patients with primary 
therapy). Moreover, criteria of biochemical curre were 
fulfilled in a shorter time when SSA was used as primary 
therapy (24.9 ± 13.3 months vs. 33 ± 15 months).
A random GH level > 1.0 ng/mL in oral glucose 
tolerance test and a decrease of IGF-1 level of at least 
50% compared to baseline were observed in 15 patients. 
GH and IGF-1 levels increased in two cases. We 
noticed a temporary increase in IGF-1 level with rela-
tively constant GH level and stabilisation of tumour 
size in one patient with microadenoma receiving SSA as 
primary therapy. The second case (B.T.) is a 36-year-old 
woman with macroadenoma (31 × 31 × 24 mm) after 
surgery followed by long-term (about five years) com-
bined pharmacotherapy (bromocriptine+octreotide/ 
/lanreotide). Regardless the therapy, adenoma size 
increased with a concomitant, significant rise in serum 
GH and IGF-1 levels.
Adenoma size reduction was noted 15 patients 
(37.5%): 12 never operated and 3 patients pre-treated 
with octreotide before neurosurgery. However, in-
crease in tumour size was marked in one patient (B.T. 
described above).
Criteria for acromegaly remission, defined as 
biochemical control together with tumour shrinkage, 
were fulfilled in 10 patients (25%): 7 not operated and 
3 patients after neurosurgery.
Common side effects included development of gall 
stones, which were diagnosed in 25% of patients after 
approximately two years of the therapy. Three patients 
required cholecystectomy. Focusing on side effects, 
persistent gastrointestinal distress was observed in 
two patients.
A comparison of efficacy of SSA therapy in non-
functioning pituitary adenomas and acromegaly is 
presented in Table III.
Discussion
Considering the main goal of NFPA therapy, which is a 
decrease in tumour volume, surgery is the current first-
choice treatment. With reference to this goal, the use of 
somatostatin analogues appears to be somewhat con-
troversial as they provide only stabilisation of tumour 
size in the overwhelming majority of cases (68% in our 
clinical study). However, stabilisation of tumour size is 
a remarkable achievement of the therapy, especially 
concerning the natural history of NFPA, which shows 
that these tumours regrow and must be reoperated in 
about 50% of cases [17].
This is the second clinical study to evaluate the long-
term efficacy of somatostatin analogues in the treatment 
of NFPA. The previous one, conducted by Fusco et al., 
focused only on the use of somatostatin analogues in 
Table III. Comparison of results of somatostatin analogue therapy in acromegaly and non-functioning pituitary adenomas
Tabela III. Porównanie wyników leczenia analogami somatostatyny w akromegalii i w nieczynnych hormonalnie gruczolakach 
przysadki
Assessed clinical parameters Acromegaly NFPA
GH and IGF-1 Diminution in 95% (57.5% normalisation) –
Øtumour size ≥ 20% 37.5%
(80% with primary medical therapy)
9.0%
(100% recurrent tumours)
Tumour size stabilisation 60% 68.0%
≠tumour size with indication  
to neurosurgical treatment
2.5% 23.0%
Side effects 25% gall stones
7.5% symptomatic cholelithiasis Æ cholecystectomy
9% gall stones
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secondary therapy after incomplete surgery, and the 
follow-up period was shorter (37 ± 18 months) [9]. In 
their group of 26 patients treated with 20 mg of oc-
treotide LAR every 28 days, tumour size increased in 
19% of patients. However, comparing to their control 
group, which consisted of untreated patients with 
post-operative tumour remnants, the adenoma size 
increased in 53% of patients. Contrary to our results, no 
tumour size reduction was noted. Similarly, no changes 
in visual field were observed. Moreover, Pawlikowski et 
al. also evaluated the risk of NFPA recurrence and they 
suggest that it was 45.7% for “pure” gonadotropinomas 
and as much as 57.1% for other monohormonal types 
of NFPA [18].
Our results highlight a limited effect of SSA on 
tumour shrinkage. This can be explained by late diag-
nosis with the detection of all tumours in a stadium of 
macroadenoma, frequently with invasion and expan-
sion beyond the confines of the sella turica. However, 
the poorer effect of somatostatin analogues can be also 
explained by differences in somatostatin receptors 
expression in non-functioning pituitary adenomas. 
NFPA are characterised by variable expression of all 
SSTR apart from SSTR4, while currently available so-
matostatin analogues (octreotide and lanreotide) bind 
preferentially to SSTR2 and with lower affinity to SSTR5 
[19]. Because of strong immunostaining of SSTR1, 
which was present in 66% of examined cases of NFPA, 
we think that introduction of novel broad-spectrum 
somatostatin analogues would be more effective in the 
therapy of NFPA [20]. Moreover, considering tumour 
shrinkage, combined therapy with novel somatostatin 
analogues and dopamine agonists can presumably be 
more effective because NFPA are also characterised by 
the expression of dopamine receptor D2 [21, 22]. 
As far as postoperative treatment of clinically non-
functioning pituitary adenomas is concerned, Ferrante 
et al. suggested that radiotherapy should be used 
because it significantly decreases the risk of tumour 
recurrence or regrowth (18.4% vs. 58.4%) [2]. Introduc-
tion of new radiation techniques such as Gamma Knife 
therapy seems to be a safer choice, minimising the risk 
of side effects [23].
Our observations support the thesis that somato-
statin analogues are more effective in primary than in 
secondary therapy of acromegaly, which has already 
been suggested by some authors [24, 25].
Furthermore, young (under 40 years old) patients, 
especially with acromegaly resistant for pharmaco-
therapy (like patient B.T.), should be tested for AIP gene 
mutations because deletions of chromosome area 11q13 
are often found [26].
Conclusions
Somatostatin analogues are less effective in the treat-
ment of NFPA in comparison to their well known, 
excellent effects in acromegaly. Stabilisation of NFPA 
size observed in the majority of patients receiving SSA 
is significantly more frequent with regard to untreated 
NFPA, as was documented in our previous studies. Tu-
mour shrinkage, which is the main therapeutic goal, is 
only marked in single cases. However, strong expression 
of different SSTR subtypes in NFPA, especially SSTR1, 
observed in our immunohistochemical studies, argues 
in favour of introduction of novel broad-spectrum so-
matostatin analogues. Considering tumour shrinkage, 
combined therapy of novel somatostatin analogues 
and dopamine agonists also seems to be more effective. 
SSA are undoubtedly effective in the treatment of 
acromegaly in secondary as well as in primary therapy. 
Considering the use of somatostatin analogues in 
secondary therapy, better outcomes are achieved in 
patients who were pre-treated with SSA before planned 
surgery. However, our results were better in primary 
than in secondary therapy. This observation calls into 
question the current, routine practice of neurosurgery 
in GH-secreting adenomas.
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